Yishen Quzhuo decoction improve chronic kidney disease by regulating amino acid metabolism: An experimental validation guided by network pharmacology

Introduction: YiShen QuZhuo Decoction (YSQZD) is a clinically proven traditional Chinese medicine formula for chronic kidney disease (CKD), but its underlying mechanism lacks systematic investigation. CKD is a prevalent renal disorder with limited effective treatments, and traditional herbal medicines are gaining attention as safer alternatives. Renal tubular injury is a key pathological change in CKD, closely linked to renal interstitial fibrosis. Methods: Network pharmacology was used to predict active ingredients, key targets, and potential mechanisms of YSQZD against CKD. BATMAN-TCM, GeneCards, STRING, and DAVID databases were employed for target screening, PPI network construction, and GO/KEGG enrichment analysis. TGF-β1-induced HK-2 cell injury model was used for in vitro validation. MTT assay, immunofluorescence staining, and GC-MS-based amino acid metabolomics were performed to evaluate the efficacy and mechanism of YSQZD. Conclusion: Network pharmacology identified 19 active ingredients (score >100, based on BATMAN-TCM default high-confidence threshold and previous literature support) and 57 common targets of YSQZD and CKD. GO/KEGG analysis revealed 26 signaling pathways, including 5 amino acid metabolism-related pathways (P<0.05). In vitro experiments (n=6 biological replicates per group) showed YSQZD dose-dependently alleviated TGF-β1-induced EMT in HK-2 cells. Western blot confirmed upregulated E-cadherin and downregulated α-SMA. Amino acid metabolomics indicated YSQZD significantly regulated aspartic acid, glutamine, and leucine levels (P < 0.05). Discussion: YSQZD exerts anti-CKD effects through multi-component, multi-target, and multi-pathway mechanisms. It regulates amino acid metabolism (especially aspartic acid) and inhibits EMT, which may be associated with SLC family transporters. The findings provide a scientific basis for YSQZD's clinical application, but further in vivo and clinical studies are needed to confirm its efficacy.

Authors

Publication Details

Journal
Pharmacological Research - Modern Chinese Medicine
Published
2026-02-12
DOI
https://doi.org/10.1016/j.prmcm.2026.100776
Primary Topic
Metabolomics and Mass Spectrometry Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Yishen Quzhuo decoction improve chronic kidney disease by regulating amino acid metabolism: An experimental validation guided by network pharmacology

Wang Xiu-min, Lv Chun-yan, He Ming-ming, Liu Li et al.
Pharmacological Research - Modern Chinese Medicine
Metabolomics and Mass Spectrometry Studies
article

Yishen Quzhuo decoction improve chronic kidney disease by regulating amino acid metabolism: An experimental validation guided by network pharmacology

Wang Xiu-min, Lv Chun-yan, He Ming-ming, Liu Li, Zhong Yuan
article en

Abstract

Introduction: YiShen QuZhuo Decoction (YSQZD) is a clinically proven traditional Chinese medicine formula for chronic kidney disease (CKD), but its underlying mechanism lacks systematic investigation. CKD is a prevalent renal disorder with limited effective treatments, and traditional herbal medicines are gaining attention as safer alternatives. Renal tubular injury is a key pathological change in CKD, closely linked to renal interstitial fibrosis. Methods: Network pharmacology was used to predict active ingredients, key targets, and potential mechanisms of YSQZD against CKD. BATMAN-TCM, GeneCards, STRING, and DAVID databases were employed for target screening, PPI network construction, and GO/KEGG enrichment analysis. TGF-β1-induced HK-2 cell injury model was used for in vitro validation. MTT assay, immunofluorescence staining, and GC-MS-based amino acid metabolomics were performed to evaluate the efficacy and mechanism of YSQZD. Conclusion: Network pharmacology identified 19 active ingredients (score >100, based on BATMAN-TCM default high-confidence threshold and previous literature support) and 57 common targets of YSQZD and CKD. GO/KEGG analysis revealed 26 signaling pathways, including 5 amino acid metabolism-related pathways (P<0.05). In vitro experiments (n=6 biological replicates per group) showed YSQZD dose-dependently alleviated TGF-β1-induced EMT in HK-2 cells. Western blot confirmed upregulated E-cadherin and downregulated α-SMA. Amino acid metabolomics indicated YSQZD significantly regulated aspartic acid, glutamine, and leucine levels (P < 0.05). Discussion: YSQZD exerts anti-CKD effects through multi-component, multi-target, and multi-pathway mechanisms. It regulates amino acid metabolism (especially aspartic acid) and inhibits EMT, which may be associated with SLC family transporters. The findings provide a scientific basis for YSQZD's clinical application, but further in vivo and clinical studies are needed to confirm its efficacy.

Pharmacological Research - Modern Chinese MedicineVol. 18
Openalex Percentile: Top 59%
Metabolomics and Mass Spectrometry Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Yishen Quzhuo decoction improve chronic kidney disease by regulating amino acid metabolism: An experimental validation guided by network pharmacology — Wang Xiu-min, Lv Chun-yan, et al. · Pharmacological Research - Modern Chinese Medicine (2026) | TGRS Research Map | TGRS